Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001Erasca will also present ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations ...

EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T ...

Rajni Goyal, an integrated MSc (Honours) graduate, Department of Microbiology, College of Basic Sciences and Humanities, ...

Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after ...

Two posters will highlight new data from the company’s open-label ASCENT study of LIQ861 (YUTREPIA) in PH-ILD patients with a focus on safety, tolerability, exploratory changes in 6-minute walk ...

Details for Auron’s poster presentation are below and can be found via the AACR online itinerary planner: Abstract Number and Title: Abstract #350: AUTX-703, a Novel and Potent KAT2A and KAT2B ...

today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14 ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European ...

The highly anticipated horror sequel 28 Years Later has a huge presence at. Do you think we see new footage this week?

Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE ...